[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endothelial-injury\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endothelial-injury":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,80,113],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100615384","inflammation-severity-and-mirna-126-in-trauma-100615384",false,"NCT07291908","Inflammation Severity and miRNA-126 in Trauma","Correlation of Inflammation Severity With Pulmonary Gas Exchange and MiRNA 126 in Trauma Patients","Inclusion Criteria:\n\nAdults aged 18 years or older.\n\nPatients monitored and treated for trauma in the anesthesia intensive care units of Akdeniz University Faculty of Medicine.\n\nExclusion Criteria:\n\nPatients younger than 18 years.\n\nPatients with concomitant thoracic trauma.\n\nPresence of active infection prior to trauma.\n\nPatients not admitted to the ICU within the first 24 hours after trauma.\n\nPatients who remain in the ICU for less than 72 hours following trauma.\n\nCurrent use of steroids, chemotherapy, or antibiotic therapy prior to ICU admission.\n\nPatients with immunodeficiency.\n\nPatients who are in shock prior to or during ICU admission.",true,"ALL","18 Years",{"count":20,"type":21},130,"ESTIMATED","OBSERVATIONAL","Trauma triggers a complex immune response intended to eliminate danger signals and restore physiological balance. Early post-traumatic inflammation is primarily initiated by damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs). In patients with severe trauma, dysregulated inflammation increases susceptibility to infection, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), and mortality. The lungs are particularly vulnerable, and excessive inflammatory activation may lead to acute lung injury (ALI) or acute respiratory distress syndrome (ARDS), conditions characterized by increased vascular permeability, alveolar epithelial injury, surfactant dysfunction, and impaired gas exchange.\n\nPro-inflammatory cytokines, activated neutrophils, reactive oxygen species, and proteases contribute to endothelial and epithelial barrier disruption. Recent evidence also suggests that several microRNAs, including miR-126, may play a regulatory role in pulmonary barrier integrity through modulation of tight-junction proteins and PI3K\u002FAKT-related pathways.\n\nAlthough many components of the trauma-related inflammatory response have been described, the relationship between systemic inflammatory severity and impairment of pulmonary gas exchange remains insufficiently defined in clinical settings.\n\nThis study aims to investigate the correlation between inflammatory severity markers (C-reactive protein, procalcitonin, IL-6, reactive oxygen derivatives, neutrophil-to-lymphocyte ratio, lactate), imaging findings (flow-mediated dilation by ultrasound), clinical parameters (blood pressure, heart rate, urine output, vasoactive medication requirements), pulmonary gas-exchange measurements (arterial blood gases, PaO₂\u002FFiO₂ ratio), and circulating miRNA-126 levels in trauma patients. The findings may help identify biomarkers that better reflect inflammatory burden and the risk of lung dysfunction following trauma.",[25,26],"Trauma ICU Patients","Endothelial Injury",[28,29,30,31],"ARDS","MULTITRAUMA","MICRORNAS","ENDOTHEL","RECRUITING","2025-12-05",{"date":35,"type":36},"2025-12-18","ACTUAL",{"date":38,"type":36},"2025-06-17",{"date":40,"type":21},"2027-01-10",{"name":42,"class":43},"Melike Cengiz","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":44},"100611763","probing-the-role-of-mitochondrial-oxidative-stress-in-impaired-vascular-function-among-young-adults-with-early-life-adversity-100611763","NCT07244809","Probing the Role of Mitochondrial Oxidative Stress in Impaired Vascular Function Among Young Adults With Early Life Adversity","PROMISE","Inclusion Criteria:\n\n* 18-29 years\n* ACE score \\>=4\n\nExclusion Criteria:\n\n* Resting arterial blood pressure \\>140\u002F90 mmHg\n* BMI \\\u003C=17 or \\>= 35\n* Are on a weight-loss diet or involved in a formal weight-loss program or are not intentionally weight stable for 6 months (+\u002F- 5 kg) prior to the study.\n* Cardiovascular or metabolic prescription drug use\n* Vasoactive antidepressant drug use (SSRIs and clonidine)\n* Current heavy alcohol use, as defined as binge drinking on 5 or more days in the last month, or consuming more than 7 (women) or 14 (men) drinks per week in the last month (per NIAAA definition)\n* Current or recent (within the last 6 mo.) illicit drug use disorder as indicated by a score of 3 or greater on the Drug Abuse Screening Test (DAST-10)\n* Current tobacco or nicotine use\n* Vaping\n* Regular vigorous (\\>6 METs) aerobic exercise (\\>4 bouts\u002Fweek, \\>30 min\u002Fbout)\n* dietary supplementation with antioxidants or habitual use of NSAIDs\n* Currently pregnant or breastfeeding","29 Years",{"count":54,"type":21},300,"INTERVENTIONAL",[57],"NA","Adverse childhood experiences (ACEs) represent highly stressful events in the first 18 years of life that include abuse, neglect, and household and community-level dysfunction. Greater exposure to ACEs are associated with greater increases in the risk of cardiovascular diseases and death. Our laboratory has previously observed that vascular function is disrupted in young adults with prior ACE exposure, even though these individuals appear to be healthy clinically (i.e., no classic clinical cardiovascular disease risk factors). There is a need to identify and understand the biological mechanisms underlying these vascular impairments to inform effective interventions to reduce cardiovascular risks the millions of individuals affected by ACEs.\n\nThe body's response to stress is coordinated across various systems, all of which depend on energy supplied by mitochondria (often referred to as the \"powerhouse of cells\"). Based on new evidence across multiple physiological systems from our team, our overarching hypothesis is that disruption of mitochondrial function contributes to cardiovascular impairments among young adults with ACEs. Here we propose the initial pilot work necessary to begin to understand these associations, which will directly inform identification of individuals who may be most vulnerable to stress-related cardiovascular risk and the development of interventions to promote cardiovascular-stress resilience.\n\nOur aims are to:\n\n1. Determine whether mitochondrial oxidative stress contributes to impaired vascular function among young adults who experienced early life adversity.\n2. Determine whether reducing mitochondrial oxidative stress improves the cellular stress and integrated cardiovascular response to laboratory-based psychosocial stress among young adults who experienced early life adversity.",[60,61,26,62,63,64],"Adverse Childhood Experience","Endothelial Function (FMD)","Mitochondrial Function","Oxidative Stress","Psychosocial Influence on Cardiovascular Disease",[66,67,68,69,70],"flow mediated dilation","mitoquinone mesylate","placebo","early life adversity","trier social stress test","2025-11-17",{"date":73,"type":36},"2025-11-24",{"date":75,"type":36},"2025-10-13",{"date":77,"type":21},"2026-12-31",{"name":79,"class":43},"University of Iowa",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":88,"minAge":18,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":55,"phases":92,"briefSummary":95,"conditions":96,"keywords":101,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":44},"100607040","phase-1-msc-exosome-therapy-for-post-preeclampsia-endothelial-dysfunction-100607040","NCT07183384","MSC Exosome Therapy for Post-Preeclampsia Endothelial Dysfunction","The Effectiveness of Mesenchymal Stem Cell-Derived Exosome Therapy in Improving Endothelial Dysfunction in Postpartum Mothers With a History of Preeclampsia","EXITPE","Inclusion Criteria:\n\n* Postpartum\n* Confirmed diagnosis of preeclampsia in the last pregnancy\n* Postpartum period of first week and second week\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* History of chronic hypertension prior to pregnancy\n* Major cardiovascular disease history\n* Active systemic infection\n* Endothelial Injury history\n* Active smoking status including vape, alcohol, drug addiction.","FEMALE","50 Years",{"count":91,"type":21},80,[93,94],"PHASE1","PHASE2","\\---\n\nWhy Is This Study Being Done?\n\nWomen who have preeclampsia during pregnancy face a much higher risk of heart disease later in life. Preeclampsia is a serious pregnancy condition that causes high blood pressure and damages blood vessels. Even after the baby is born, the blood vessels do not fully heal on their own, which can lead to heart problems\u002Fcardiovascular years later.\n\nThis study tests whether a new treatment called exosomes can help repair damaged blood vessels in women who had preeclampsia. Exosomes are tiny particles that come from stem cells and contain healing substances that may help blood vessels work better.\n\n\\---\n\nWhat Will Happen in This Study?\n\nThis study will include 80 women who recently gave birth and had preeclampsia during their pregnancy. Half of the women will receive the exosome treatment through an IV, and half will receive a placebo (a substance with no active treatment).\n\n\\---\n\nWhat Will Participants Need to Do?\n\nParticipants will:\n\n* Have blood tests and other health checks\n* Receive one treatment through an IV\n* Return for follow-up visits at 1 week after treatment\n* Have tests to check how well their blood vessels are working\n\nWho Can Join This Study?\n\nWomen who:\n\n* Recently gave birth (within 1-2 weeks)\n* Had preeclampsia during their last pregnancy\n* Are healthy enough to participate\n* Can give permission to join the study\n\nWhat Are the Possible Benefits and Risks?\n\nThe treatment may help repair blood vessel damage and reduce the risk of future heart disease. The exosome treatment appears to be safe based on other studies, but like any medical treatment, there may be side effects.\n\n\\---\n\nHow Long Will the Study Last?\n\nThe main treatment happens during one visit, with follow-up visits for 1 week to check on participants' health and see if the treatment is working.\n\nThis research may lead to new ways to protect women's heart health after pregnancy complications.",[97,98,26,99,100],"Preeclampsia","Postpartum","Exosome Multiomics","Cell Therapy",[97,98,102,103,100],"Stem Cell","Exosome","2025-09-12",{"date":106,"type":36},"2025-09-19",{"date":108,"type":36},"2024-07-01",{"date":110,"type":21},"2026-09-01",{"name":112,"class":43},"Universitas Padjadjaran",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":55,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":4},"100558320","th-tl-xb-prescription-on-reprogramming-of-lipid-metabolism-and-endothelial-injury-for-cerebral-infarction-patients-100558320","NCT06549582","Th Tl Xb Prescription on Reprogramming of Lipid Metabolism and Endothelial Injury for Cerebral Infarction Patients","Effect of Taohong Tongluo Xiaoban Prescription on Reprogramming of Lipid Metabolism and Endothelial Injury for Cerebral Infarction Patients：a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. The CT\u002FMRI examination findings were consistent with the diagnosis of Western cerebral infarction, aligning with the TCM apoplexy diagnosis. Primary stroke occurred 35±5 days ago.\n2. The National Institutes of Health Stroke Scale (NIHSS) evaluates a range of scores from 4 to 24.\n3. Coronary atherosclerotic heart disease is confirmed through coronary CT angiography. Carotid artery ultrasonography is employed to ascertain the presence or absence of plaque formation, with stable plaques exhibiting predominantly high and uneven echogenicity, while unstable plaques displayed low echo or irregular hypoechoic regions.\n4. Age range: ≥35 years to ≤80 years.\n5. First onset requires; patients with previous diseases and no sequelae such as limb paralysis should not affect the NIHSS score, and the modified Rankin scale (mRS) score should be ≤1 point.\n6. Patient informed consent must be obtained.\n7. The criteria for the syndrome of phlegm and blood stasis are as follows: Main syndrome: hemiplegia, mouth and eyes skew, speech retarding or silent, sensation diminished or disappeared; Secondary syndrome: excessive sputum, fat tongue with teeth marks on the side, dark red tongue, sublingual vein blue or tortuous, tongue spots, white or thick greasy fur, pulse slippery.\n\n   \\-\n\nExclusion Criteria:\n\n1. subarachnoid hemorrhage, transient ischemic attack, or other intracranial lesions such as intracranial tumor, aneurysm, vascular malformation, cerebral cysticercosis, intracerebral schistosomiasis, encephalitis, meningitis, hydrocephalus, and sequelae of brain trauma; Nonatherosclerotic thrombotic cerebral infarction (e.g., cardiogenic embolism, hypercoagulability disorders, endovascular shedding and arteritis);\n2. onset occurring within a range of 30 to 40 days；\n3. The patient presents with limb motor dysfunction, emotional disorder, cognitive impairment, or speech impairment resulting from pre-existing conditions (e.g., surgery, trauma, or congenital disability) prior to the onset of cerebrovascular accident.\n4. Patients with severe cardiac disease, heart failure, liver or kidney failure, malignant tumors, gastrointestinal bleeding, severe infections, or uncontrolled diabetes are excluded from the study.\n5. Individuals currently participating in other clinical trials are not eligible for inclusion.\n6. Exclusion criteria include patients with mental illness, multiple body ulcers or joint contractures.\n7. Non-compliance with treatment by patients and their families is considered an exclusion criterion.\n8. Inability to comprehend the content of informed consent and inability to provide a signature on the informed consent form are also grounds for exclusion.\n9. . Pregnant and lactating women are excluded from participation.\n\n   \\-","35 Years","80 Years",{"count":123,"type":21},160,[57],"This study is a prospective, open-label, randomized control trial. It is planning to include 160 cerebral infarction patients which will be randomized in a 1﹕1 fashion to receive Chinese herbal medicines combined basic medicine treatment, or to receive standard basic medicine treatment within 3 months after inclusion. Follow-up will be performed after the treatment for 3 months to evaluate the incidence and disability rates of limb impairment, language impairment, cognitive impairment, and emotional disorders. The primary outcome is modified Rankin Scale Score, which is measured by the overall distribution from 0 (no symptoms) to 6 (death). The secondary outcome include the Evaluation of Neurological Function Deficit score (National Institute of Health stroke scale scoring) and carotid atherosclerotic plaque score (Crouse scoring system for neck carotid atherosclerotic plaque scoring). Additional outcomes include laboratory indicator to analysis the reprogramming of lipid metabolism and endothelial Injury, Chinese medicine symptom and sign scoring system and biological indicators. The investigators will perform the intention-to-treat analysis for withdrawal and missing data, and estimate the health economic value.",[127,128,129,130,26],"Cerebral Infarction","Chinese Herbal Medicine","Clinical Trial","Lipid Metabolism Disorder","NOT_YET_RECRUITING","2024-08-11",{"date":134,"type":36},"2024-08-14",{"date":136,"type":21},"2024-10",{"date":138,"type":21},"2026-12",{"name":140,"class":43},"Yan Zhu"]